3.0

	÷			ś	1	1	ŀ	1		*	*		٠			*	
		12								Xe	Xe	×	×				Xe
		11								Xe	Xe	Xe	×e				
150		10								Xe	Хе	Xe	×e			Xe	
2007013		6			7					Xe	Xe	Xe	š				
		œ								Xe	Xe	Xe	Xe			Xe	
		7								Xe	Xe	Xe	Xe			_	Н
		9:	П	1				xc	×	×e	×e	Xe	Xe				Xe
124		2	П	1						×e	ş	Xe	Xe				
700		.4	Н	+			-		_	×	×e	Xe	Xe		-	×e	
		3		-	-	_		_	_	×e	×e	×e	×e		F	Ĥ	
45	1	2		-				xc	×	×	×	×	\vdash			-	H
99	9	1			_			×	×	-	×	ļ	H		_		
17 24 31 38	\$tabox3		H	-				XBX	×	×	×	×	×	-		_	_
Δ,	4 5			-	_			XBX	×	-	-	×				-	-
7				-					H	-	┡	-	-			_	
-	8			-	_			X	×	-	-	×	×	_			
10	2			_				×	×	×	×	×	×	-	_		
_				_			×				-	_		-		L	
~ ·									×	×	×	×	×				
2 0 P						×	L		_	L	L	L	L	L			
.20 3 5		i.			×				L	×	×	×	×	×	×		×
424 56 36				×													
				7	. 20					E				1.17			
					ent		gide			9		કારા		6			2
A) (Tee	10	Stand			0,000		ophosopomide			900	ن	30	alos		/X	â	
(A)	0	0		(90)	(1) (E) (E)		100		Salvie.	stolic Physical Exam.	6	State State of State State	mesoli la los mesos	a de la constante de la consta		×	
2		Š		Ž.	0.0	10	8	No.		1	3,0	9	(6)		183	ő	15

This can be extended up to -56 days only if an additional procedure is needed to establish that the patient is melanoma-free prior to andomization

History/Physical Exam, Vital Signs, Performance Status, Routine Labs, Chest X-Ray q2 months in year 2, q3 months in year 3, then q6 months through year 5; CT or MRI at 18, 24, and 36 months (chest x-ray omitted if CT/MRI scheduled) 0.1 mL of a 1:10 dilution of Tice BCG (Tice-A) mixed with vaccine

0.1 mL of a 1:100 dilution of Tice BCG (Tice-B) mixed with vaccine **\$22** #

0.1 mL of a 1:1000 dilution of Tice BCG (Tice-C) mixed with vaccine

This can be extended up to -34 days if an additional procedure is needed to establish that the patient is melanoma-free prior to randomization

Routine Labs: hematology (CBC with differential, platelet count), BUN or creatinine, LDH, SGOT, alkaline phosphatase, electrolomes End of Treatment Month

×